Cognitive impairment and biomarkers of gut microbial translocation in testicular germ cell tumor survivors

Chovanec, Michal; Kalavska, Katarína; Obertová, Jana; Palacka, Patrik; Rejleková, Katarína; Syčová-Milá, Zuzana; Országhová, Zuzana; Lesko, Peter; Angelis, Valentina De; Vasiľková, Lucia; Světlovská, Daniela; Mladosievičová, Beáta; Mardiak, Jozef; Pastorek, Michal; Vlková, Barbora; Celec, Peter; Mego, Michal

doi:10.3389/fonc.2023.1146032

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher fecal abundance of Akkermansia , Ruminococcus , Bacteroides , and Faecalibacterium was associated with an improved therapy response [ 173 ]. A very recently published analysis of peripheral blood in 142 cured oncology patients with testicular germ cell tumors pointed to the association of the biomarker sCD14, which plays a role in microbial translocation and monocyte activation via LPS, with reduced cognitive functions after cisplatin treatment [ 174 ].…”

Section: Microbiome and Therapy-induced Late Effectsmentioning

confidence: 99%

Microbiome in Cancer Development and Treatment

Ciernikova,

Sevcikova,

Mladosievicova

et al. 2023

Microorganisms

Self Cite

View full text Add to dashboard Cite

Targeting the microbiome, microbiota-derived metabolites, and related pathways represents a significant challenge in oncology. Microbiome analyses have confirmed the negative impact of cancer treatment on gut homeostasis, resulting in acute dysbiosis and severe complications, including massive inflammatory immune response, mucosal barrier disruption, and bacterial translocation across the gut epithelium. Moreover, recent studies revealed the relationship between an imbalance in the gut microbiome and treatment-related toxicity. In this review, we provide current insights into the role of the microbiome in tumor development and the impact of gut and tumor microbiomes on chemo- and immunotherapy efficacy, as well as treatment-induced late effects, including cognitive impairment and cardiotoxicity. As discussed, microbiota modulation via probiotic supplementation and fecal microbiota transplantation represents a new trend in cancer patient care, aiming to increase bacterial diversity, alleviate acute and long-term treatment-induced toxicity, and improve the response to various treatment modalities. However, a more detailed understanding of the complex relationship between the microbiome and host can significantly contribute to integrating a microbiome-based approach into clinical practice. Determination of causal correlations might lead to the identification of clinically relevant diagnostic and prognostic microbial biomarkers. Notably, restoration of intestinal homeostasis could contribute to optimizing treatment efficacy and improving cancer patient outcomes.

show abstract

Section: Microbiome and Therapy-induced Late Effectsmentioning

confidence: 99%